SK772001A3 - Heterocyclic compounds as inhibitors of rotamase enzymes - Google Patents
Heterocyclic compounds as inhibitors of rotamase enzymes Download PDFInfo
- Publication number
- SK772001A3 SK772001A3 SK77-2001A SK772001A SK772001A3 SK 772001 A3 SK772001 A3 SK 772001A3 SK 772001 A SK772001 A SK 772001A SK 772001 A3 SK772001 A3 SK 772001A3
- Authority
- SK
- Slovakia
- Prior art keywords
- compound
- formula
- alkyl
- group
- benzoxazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9815880.1A GB9815880D0 (en) | 1998-07-21 | 1998-07-21 | Heterocycles |
| PCT/IB1999/001211 WO2000005232A1 (fr) | 1998-07-21 | 1999-06-28 | Composes heterocycliques inhibiteurs d'enzymes rotamase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK772001A3 true SK772001A3 (en) | 2001-12-03 |
Family
ID=10835920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK77-2001A SK772001A3 (en) | 1998-07-21 | 1999-06-28 | Heterocyclic compounds as inhibitors of rotamase enzymes |
Country Status (45)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9815696D0 (en) * | 1998-07-20 | 1998-09-16 | Pfizer Ltd | Heterocyclics |
| GB9815880D0 (en) * | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
| BR9915013A (pt) | 1998-11-03 | 2001-08-07 | Basf Ag | Composto, uso dos mesmos, processo para preparar os mesmos, droga, e, método para detecção in vitro para inibidores parp |
| GT200000203A (es) | 1999-12-01 | 2002-05-24 | Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas. | |
| FR2805818B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
| DE10124953A1 (de) * | 2001-05-21 | 2002-12-12 | Marlies Knipper | Substanz für die therapeutische Behandlung von Tinnitus |
| DK1778637T3 (da) * | 2004-06-29 | 2012-06-18 | Aventis Pharma Inc | FKBP-bindingssammensætninger og farmaceutisk anvendelse deraf |
| TWI375673B (en) * | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| US7728026B2 (en) * | 2005-04-11 | 2010-06-01 | Abbott Laboratories, Inc. | 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors |
| EP1957477B1 (fr) * | 2005-09-29 | 2011-12-07 | Abbott Laboratories | 1h-benzimidazole-4-carboxamides a substitution phenyle en position 2, utilises comme inhibiteurs de la parp |
| TW200736229A (en) * | 2005-11-15 | 2007-10-01 | Abbott Lab | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors |
| EP3205644A1 (fr) | 2005-12-29 | 2017-08-16 | Celtaxsys Inc. | Dérivés de diamine en tant qu'inhibiteurs d'hydrolase a4 de leucotriène |
| RU2462458C2 (ru) * | 2006-02-10 | 2012-09-27 | Байомарин Ига Лимитед | Лечение миодистрофии дюшена |
| GB0602768D0 (en) * | 2006-02-10 | 2006-03-22 | Vastox Plc | Treatment of muscular dystrophy |
| WO2007091106A2 (fr) | 2006-02-10 | 2007-08-16 | Summit Corporation Plc | Traitement de la dystrophie musculaire de duchenne |
| ATE553104T1 (de) * | 2006-05-02 | 2012-04-15 | Abbott Lab | Substituierte 1h-benzimidazol-4-carboxamide als potente parp-hemmer |
| AU2007338793B2 (en) * | 2006-12-20 | 2012-05-03 | Amgen Inc. | Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer |
| AR065628A1 (es) * | 2007-03-07 | 2009-06-17 | Xenon Pharmaceuticals Inc | Compuestos triciclicos de utilidad en el tratamiento de trastornos por carencia de hierro en el organismo |
| US8067613B2 (en) * | 2007-07-16 | 2011-11-29 | Abbott Laboratories | Benzimidazole poly(ADP ribose)polymerase inhibitors |
| CN101678107A (zh) * | 2007-08-03 | 2010-03-24 | 萨米特公开有限公司 | 用于治疗杜兴型肌营养不良的药物组合物 |
| GB0715939D0 (en) * | 2007-08-15 | 2007-09-26 | Vastox Plc | Method of treatment of duchenne muscular dystrophy |
| GB0715937D0 (en) * | 2007-08-15 | 2007-09-26 | Vastox Plc | Method of treatment og duchenne muscular dystrophy |
| DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
| WO2010083199A1 (fr) * | 2009-01-19 | 2010-07-22 | Abbott Laboratories | Inhibiteurs benzthiazole de la poly(adp-ribose)polymérase |
| GB0905664D0 (en) * | 2009-04-02 | 2009-05-13 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| RU2686101C2 (ru) | 2013-03-12 | 2019-04-24 | Селтакссис, Инк. | Способы ингибирования лейкотриен- а4-гидролазы |
| EP2970309A4 (fr) | 2013-03-14 | 2016-11-09 | Celtaxsys Inc | Inhibiteurs de la leucotriène a4 hydrolase |
| MX2015011677A (es) | 2013-03-14 | 2016-07-08 | Celtaxsys Inc | Inhibidores de leucotrieno a4 hidrolasa. |
| EP2968265A4 (fr) | 2013-03-14 | 2016-12-28 | Celtaxsys Inc | Inhibiteurs de la leucotriène a4 hydrolase |
| AU2015264336B2 (en) * | 2014-05-19 | 2018-08-30 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic compounds |
| EP3801559A4 (fr) | 2018-05-31 | 2022-03-02 | Celltaxis, LLC | Procédé de réduction d'exacerbations pulmonaires chez des patients atteints d'une maladie respiratoire |
| CN109111376B (zh) * | 2018-09-18 | 2021-09-14 | 四川医立特生物医药有限公司 | 一种2,5-双脱氧链霉胺衍生物及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612332A (en) * | 1984-03-19 | 1997-03-18 | Alteon Inc. | Di- and triaminoguanidines, and methods of use |
| JPS6428245A (en) | 1987-07-22 | 1989-01-30 | Sumitomo Electric Industries | Production of fluoride glass |
| MX9202466A (es) | 1991-05-24 | 1994-06-30 | Vertex Pharma | Compuestos inmunosupresores novedosos. |
| CO4520280A1 (es) * | 1993-10-26 | 1997-10-15 | Boehringer Ingelheim Pharma | Derivados de pirrolidina, inhibidores de la bioscientesis de leucotrienos |
| DE19514313A1 (de) | 1994-08-03 | 1996-02-08 | Bayer Ag | Benzoxazolyl- und Benzothiazolyloxazolidinone |
| US5696135A (en) * | 1995-06-07 | 1997-12-09 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth |
| US5859031A (en) | 1995-06-07 | 1999-01-12 | Gpi Nil Holdings, Inc. | Small molecule inhibitors of rotamase enzyme activity |
| US5801197A (en) * | 1995-10-31 | 1998-09-01 | Gpi Nil Holdings, Inc. | Rotamase enzyme activity inhibitors |
| US5801187A (en) * | 1996-09-25 | 1998-09-01 | Gpi-Nil Holdings, Inc. | Heterocyclic esters and amides |
| US5786378A (en) * | 1996-09-25 | 1998-07-28 | Gpi Nil Holdings, Inc. | Heterocyclic thioesters |
| US5840736A (en) | 1996-11-13 | 1998-11-24 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
| US5811434A (en) | 1996-11-13 | 1998-09-22 | Vertex Pharmacueticals Incorporated | Methods and compositions for stimulating neurite growth |
| US5780484A (en) | 1996-11-13 | 1998-07-14 | Vertex Pharmaceuticals Incorporated | Methods for stimulating neurite growth with piperidine compounds |
| US5721256A (en) | 1997-02-12 | 1998-02-24 | Gpi Nil Holdings, Inc. | Method of using neurotrophic sulfonamide compounds |
| GB9815696D0 (en) * | 1998-07-20 | 1998-09-16 | Pfizer Ltd | Heterocyclics |
| GB9815880D0 (en) * | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
-
1998
- 1998-07-21 GB GBGB9815880.1A patent/GB9815880D0/en not_active Ceased
-
1999
- 1999-06-28 ID IDW20010155A patent/ID26991A/id unknown
- 1999-06-28 GE GEAP19995715A patent/GEP20033028B/en unknown
- 1999-06-28 CN CNB998089974A patent/CN1174978C/zh not_active Expired - Fee Related
- 1999-06-28 SI SI9930246T patent/SI1100797T1/xx unknown
- 1999-06-28 NZ NZ522270A patent/NZ522270A/en unknown
- 1999-06-28 WO PCT/IB1999/001211 patent/WO2000005232A1/fr not_active Application Discontinuation
- 1999-06-28 CN CNA2003101239079A patent/CN1511837A/zh active Pending
- 1999-06-28 KR KR10-2001-7000927A patent/KR100450008B1/ko not_active IP Right Cessation
- 1999-06-28 CN CNA2004100399747A patent/CN1611499A/zh active Pending
- 1999-06-28 EE EEP200100044A patent/EE200100044A/xx unknown
- 1999-06-28 DE DE69905582T patent/DE69905582T2/de not_active Expired - Fee Related
- 1999-06-28 AU AU42858/99A patent/AU765925B2/en not_active Ceased
- 1999-06-28 OA OA1200100023A patent/OA11585A/en unknown
- 1999-06-28 CA CA002338214A patent/CA2338214C/fr not_active Expired - Fee Related
- 1999-06-28 PL PL99345734A patent/PL345734A1/xx not_active Application Discontinuation
- 1999-06-28 DK DK99963123T patent/DK1100797T3/da active
- 1999-06-28 AT AT99963123T patent/ATE233261T1/de not_active IP Right Cessation
- 1999-06-28 JP JP2000561188A patent/JP3795329B2/ja not_active Expired - Fee Related
- 1999-06-28 BR BR9912330-4A patent/BR9912330A/pt not_active Application Discontinuation
- 1999-06-28 EP EP99963123A patent/EP1100797B1/fr not_active Expired - Lifetime
- 1999-06-28 AP APAP/P/2001/002046A patent/AP2001002046A0/en unknown
- 1999-06-28 TR TR2001/00135T patent/TR200100135T2/xx unknown
- 1999-06-28 HU HU0103413A patent/HUP0103413A3/hu unknown
- 1999-06-28 ES ES99963123T patent/ES2191484T3/es not_active Expired - Lifetime
- 1999-06-28 KR KR10-2004-7007852A patent/KR100468185B1/ko not_active IP Right Cessation
- 1999-06-28 SK SK77-2001A patent/SK772001A3/sk unknown
- 1999-06-28 NZ NZ508838A patent/NZ508838A/xx unknown
- 1999-06-28 EA EA200100052A patent/EA003513B1/ru not_active IP Right Cessation
- 1999-06-28 IL IL14024499A patent/IL140244A0/xx unknown
- 1999-07-07 HN HN1999000106A patent/HN1999000106A/es unknown
- 1999-07-13 TW TW088111868A patent/TWI229672B/zh not_active IP Right Cessation
- 1999-07-19 CO CO99045677A patent/CO5080782A1/es unknown
- 1999-07-19 AR ARP990103544A patent/AR019427A1/es unknown
- 1999-07-20 CR CR6073A patent/CR6073A/es not_active Application Discontinuation
- 1999-07-20 GT GT199900115A patent/GT199900115A/es unknown
- 1999-07-20 MA MA25691A patent/MA24936A1/fr unknown
- 1999-07-20 MY MYPI99003048A patent/MY118222A/en unknown
- 1999-07-20 DZ DZ990151A patent/DZ2851A1/fr active
- 1999-07-20 TN TNTNSN99147A patent/TNSN99147A1/fr unknown
- 1999-07-20 PA PA19998478501A patent/PA8478501A1/es unknown
- 1999-07-20 PE PE1999000727A patent/PE20001037A1/es not_active Application Discontinuation
- 1999-07-20 SV SV1999000102A patent/SV1999000102A/es not_active Application Discontinuation
- 1999-07-21 US US09/358,107 patent/US6372736B1/en not_active Expired - Fee Related
-
2000
- 2000-12-22 IS IS5790A patent/IS5790A/is unknown
-
2001
- 2001-01-19 HR HR20010052A patent/HRP20010052A2/hr not_active Application Discontinuation
- 2001-01-19 NO NO20010322A patent/NO20010322L/no not_active Application Discontinuation
- 2001-02-14 BG BG105254A patent/BG105254A/xx unknown
-
2002
- 2002-01-23 US US10/056,901 patent/US6562964B1/en not_active Expired - Fee Related
- 2002-02-06 HK HK02100933.8A patent/HK1039779A1/zh unknown
-
2003
- 2003-04-09 JP JP2003105099A patent/JP2004002374A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK772001A3 (en) | Heterocyclic compounds as inhibitors of rotamase enzymes | |
| CA2938169C (fr) | Composes d'aza bicyclique comme agonistes de recepteur muscarinique m1 | |
| EP0976732B1 (fr) | Derives amines cycliques 1,4-substitues | |
| AU2006255944B2 (en) | Heterocyclic compound | |
| US5817677A (en) | 5-membered heterocycles, medicaments containing these compounds, their use and processes for their preparation | |
| US5629325A (en) | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission | |
| JP5706337B2 (ja) | （とりわけ）糖尿病の予防または治療に有用なｎ−アシル−ｎ’−フェニルピペラジンの誘導体 | |
| EP1060178B1 (fr) | Composes heterocycliques utilises en tant qu'inhibiteurs des enzymes rotamases | |
| CA2315117C (fr) | Composes ether et thioether heterocycliques utilises dans la regulation de la transmission synaptique chimique | |
| CA2873850C (fr) | Derives de sulfonylpiperidine et leur utilisation pour le traitement de maladies mediees par une prokineticine | |
| WO2002006234A1 (fr) | Derives de sulfonate, procede de production et utilisation de ces derives | |
| JP2001302633A (ja) | 環状アミン化合物、その製造法および用途 | |
| NO325449B1 (no) | Prolinderivater, farmasoytisk sammensetning, terapeutisk middel og DPP-IV-inhibitor | |
| JP2010523530A (ja) | タンパク質キナーゼ阻害剤として有益な［２，６］ナフチリジン | |
| US6437138B1 (en) | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission | |
| AU4385599A (en) | Fkbp inhibitors | |
| CZ2001236A3 (cs) | Heterocyklické sloučeniny jako inhibitory rotamasy |